Having demonstrated that the deregulation of TCL1b resulted in angiosarcoma and positive immunohistochemistry of TCL1b in human angiosarcoma and various human cancer types, we attempted to design the inhibitory peptides based on the amino-acid sequences and the three-dimensional predicted structure of TCL1b. Here, TCL1B is linked to angiosarcoma.